Abstract: Disclosed herein are novel single-stranded anti-sense oligonucleotides (ASOs) capable of reducing the transcription of thioredoxin domain containing protein 5 (TXNDC5) mRNA. Also disclosed is use of the single-stranded ASOs as disclosed herein for manufacturing medicaments suitable for treating a disease associated with upregulation of TXNDC5. Accordingly, a pharmaceutical composition comprising the disclosed ASO molecules is provided; as well as a method of treating a subject suffering from TXNDC5-mediated disease via administering to the subject the disclosed single-stranded ASO molecules.

Abstract: Disclosed herein is a chimeric antigen receptor (CAR) comprising a single-chain variable fragment specific to Globo H, a hinge and transmembrane domain, a co-stimulatory molecule, and a cytoplasmic domain. According to some embodiments of the present disclosure, the CAR further comprises a single-chain variable fragment specific to PD-L1, and optionally, a fragment crystallizable region of an immunoglobulin. Also disclosed herein are isolated nucleic acids encoding the CAR pharmaceutical kits comprising the isolated immune cells expressing the CAR, and methods of treating cancers by using isolated immune cells.

Abstract: A method for ex vivo treating blood or plasma is provided. The method includes (a) ex vivo contacting a blood or plasma with an enzyme composition to react the enzyme composition with the blood or plasma, wherein the enzyme composition is capable of eliminating electronegative low-density lipoprotein from the blood or plasma by the activity of the enzyme composition, and the enzyme composition is selected from a group consisting of: a first enzyme for eliminating a glycan residue of an electronegative low-density lipoprotein (LDL); a second enzyme for eliminating ceramide carried by a electronegative low-density lipoprotein (LDL); and a combination thereof; and (b) terminating contact between the blood or plasma and the enzyme composition to terminate the reaction of the enzyme composition with the blood or plasma.

Abstract: A method of preparing fiber includes blending bio-compatible ceramic powder and first polyester to form a ceramic powder composition, wherein the bio-compatible ceramic powder and the first polyester have a weight ratio of 10:90 to 60:40. The method further includes blending the ceramic powder composition and second polyester to form a composite material, wherein the ceramic powder composition and the second polyester have a weight ratio of 0.4:99.6 to 40:60. The method also spins the composite material to form a fiber. The first polyester has an intrinsic viscosity (IV) of 0.35 dL/g to 0.55 dL/g, and the second polyester has an intrinsic viscosity (IV) of 0.6 dL/g to 0.8 g/dL. The fiber can be woven to form an artificial ligament/tendon.

Abstract: A bionic fixing apparatus is provided. The bionic fixing apparatus includes a body having a through hole and at least one slit. The through hole penetrates the body from the top surface to the bottom surface to form a top opening and a bottom opening. An inner diameter of the top opening is larger than an inner diameter of the bottom opening. The slit is connected to the bottom opening and extends upwardly from the bottom surface of the body, such that the body has a flexible bottom portion.

Abstract: A method for treating skin diseases, wherein a composition having an effective amount of mangosteen rind extract is administered.

Abstract: A bionic apparatus is provided. The bionic apparatus includes a flexible portion having a plurality of pores, a rigid portion connected with the flexible portion, and a supporting element disposed in the flexible portion. The pore size of each pore is between 50 ?m to 500 ?m. The flexible portion, the rigid portion and the supporting element are one-piece formed by a additive manufacturing process.

Abstract: A method for ex vivo treating blood or plasma is provided. The method includes (a) ex vivo contacting a blood or plasma with an enzyme composition to react the enzyme composition with the blood or plasma, wherein the enzyme composition is capable of eliminating electronegative low-density lipoprotein from the blood or plasma by the activity of the enzyme composition, and the enzyme composition is selected from a group consisting of: a first enzyme for eliminating a glycan residue of an electronegative low-density lipoprotein (LDL); a second enzyme for eliminating ceramide carried by a electronegative low-density lipoprotein (LDL); and a combination thereof; and (b) terminating contact between the blood or plasma and the enzyme composition to terminate the reaction of the enzyme composition with the blood or plasma.

Abstract: Use of a composition in preparation of medicine for treating skin diseases, the composition comprising an effective dose of mangosteen rind extract.

Abstract: A bionic fixing apparatus is provided. The bionic fixing apparatus includes a flexible portion having at least one trench. The trench is disposed on the surface of the flexible portion and has a first end and a second end. An interval is disposed between the first end and the second end. The trench is disposed for spreading the stress applied on the bionic fixing apparatus and preventing stress concentration and stress shielding.

Abstract: An implant device for osseous integration includes a plurality of connection bars and at least one frame bar. These connection bars are connected with each other to form a three-dimensional (3D) grid structure. The frame bar is connected with at least two of the connection bars to define at least one edge of the 3D grid structure. Wherein, the frame bar has a diameter substantially greater than that of these connection bars.

Abstract: The present disclosure provides a biochemistry reactive material, including a substrate and an enzyme composition immobilized on the substrate. The enzyme composition is selected from a group consisting of a first enzyme, a second enzyme, and a combination thereof. The first enzyme is used for eliminating a glycan residue of an electronegative low-density lipoprotein (electronegative LDL). The second enzyme is used for eliminating ceramide carried by an electronegative low-density lipoprotein. The biochemistry reactive material is capable of eliminating electronegative low-density lipoprotein.

Abstract: A bionic fixing apparatus is provided. The bionic fixing apparatus includes a body having a through hole and at least one slit. The through hole penetrates the body from the top surface to the bottom surface to form a top opening and a bottom opening. An inner diameter of the top opening is larger than an inner diameter of the bottom opening. The slit is connected to the bottom opening and extends upwardly from the bottom surface of the body, such that the body has a flexible bottom portion.

Abstract: A bionic apparatus is provided. The bionic apparatus includes a flexible portion having a plurality of pores, a rigid portion connected with the flexible portion, and a supporting element disposed in the flexible portion. The pore size of each pore is between 50 ?m to 500 ?m. The flexible portion, the rigid portion and the supporting element are one-piece formed by a additive manufacturing process.

Abstract: A bionic fixing apparatus is provided. The bionic fixing apparatus includes a flexible portion having at least one trench. The trench is disposed on the surface of the flexible portion and has a first end and a second end. An interval is disposed between the first end and the second end. The trench is disposed for spreading the stress applied on the bionic fixing apparatus and preventing stress concentration and stress shielding.

Abstract: In an embodiment of the disclosure, a biomedical material is provided. The biomedical material includes a biocompatible material having a surface and a carrier distributed over the surface of the biocompatible material, wherein both of the biocompatible material and the carrier have no charges, one of them has charges or both of them have charges with different electricity. The biomedical material is utilized for dentistry, orthopedics, wound healing or medical beauty and applied in the repair and regeneration of various soft and hard tissues.

Abstract: The disclosure provides a pharmaceutical composition for promoting wound healing, including an effective amount of a Sambucus plant or an Isatis plant as an active ingredient for promoting wound healing; and a pharmaceutically acceptable carrier or medium, wherein the Sambucus plant is Sambucus formosana Nakai, and the Isatis plant is Isatis indigotica Fort.

Abstract: In an embodiment of the disclosure, a biomedical material is provided. The biomedical material includes a biocompatible material having a surface and a carrier distributed over the surface of the biocompatible material, wherein both of the biocompatible material and the carrier have no charges, one of them has charges or both of them have charges with different electricity. The biomedical material is utilized for dentistry, orthopedics, wound healing or medical beauty and applied in the repair and regeneration of various soft and hard tissues.

Abstract: A pharmaceutical mixture for the treatment of hepatitis and its preparation method are disclosed. The method includes the following steps: pulverize the plants, macerate and extract the plant with water, concentrate the aqueous extract as the first concentrate; add ethanol to form a precipitate, collect and concentrate the liquid phase to form the second concentrate, and dry it; pass the second concentrate through the resin, elute with water, water-ethanol mixture and ethanol, collect and concentrate the water-ethanol and ethanol elution fraction as the third concentrate, and dry it. The plants in the present invention are Boehmeria frutescens Thunberg, Boehmeria nivea or the nettle family.

Abstract: A pharmaceutical mixture for the treatment of hepatitis and its preparation method are disclosed. The method includes the following steps: pulverize the plants, macerate and extract the plant with water, concentrate the aqueous extract as the first concentrate; add ethanol to form a precipitate, collect and concentrate the liquid phase to form the second concentrate, and dry it; pass the second concentrate through the resin, elute with water, water-ethanol mixture and ethanol, collect and concentrate the water-ethanol and ethanol elution fraction as the third concentrate, and dry it. The plants in the present invention are Boehmeria frutescens Thunberg, Boehmeria nivea or the nettle family.